DAX+0,53 % EUR/USD+0,16 % Gold+0,24 % Öl (Brent)+1,18 %

Neoprobe + 62%, höchster Umsatz seit 2000 (nur für Zocker) - 500 Beiträge pro Seite



Beitrag schreiben

Begriffe und/oder Benutzer

 

Hallo, hier habe ich etwas für Zocker. Wer einsteigen will - bitte in den USA

Charttech. kann es schnell Richtung 0,50 $ gehen. Dies ist aber keine Kaufempfehlung.

WKN: 885701


Sep. 8, 2003 11:53 ET Market Open
Common Stock Market: OTCBB

Last Sale $ 0.228
Change Net / % 0.088 62.86%
Best Bid / Ask $ 0.21 $ 0.23
Today`s High / Low $ 0.28 $ 0.16
Share Volume 1,553,100
Previous Close $ 0.14
52 Wk High / Low $ 0.31 $ 0.05


Neoprobe Receives Marketing Clearance for Quantix/OR in United States; Quantix/OR To Be Delivered to Clinical Sites

DUBLIN, Ohio, Sep 8, 2003 (BUSINESS WIRE) -- Neoprobe Corporation (OTCBB:NEOP), today announced that it had received clearance from the United States Food and Drug Administration to begin commercial marketing of the Quantix/OR(TM) system for the intraoperative measurement of blood flow. The Quantix/OR received marketing clearance under a U.S. FDA 510(k) application.

David Bupp, Neoprobe`s President and CEO, said, "the marketing clearance of the Quantix/OR will allow us to commence the clinical evaluation of the Quantix/OR at leading institutions in the United States. The activity at institutions in United States will supplement the evaluations already underway in Europe and Asia and will support our efforts to develop a U.S. market for the Quantix/OR through one or more established national sales representative organizations."

Dr. Richard Orahood, Neoprobe`s Medical Director, said, "the commencement of clinical evaluation of the Quantix/OR will be an important next step in the commercialization of the Quantix/OR. To date, the clinical evaluations in Europe by leading cardiothoracic surgery departments have shown the important innovation represented by the Quantix technology."

The first evaluating site for the Quantix/OR in the United States will be Boston University Medical Center. Dr. Oz Shapira, Clinical Director of Cardiothoracic Surgery at Boston University said, "our research with the Quantix/OR in animal studies makes us confident that the Quantix/OR will permit easy and accurate measurement of blood flow volume in a variety of clinical settings."

The Quantix/OR is designed to allow cardiothoracic and vascular surgeons to measure blood flow in a simple and real-time manner during intraoperative procedures. Quantix/OR consists of an angle-independent ultrasound probe that obtains signals directly from the blood vessel and measures blood flow in the vessel regardless of vessel size. The Quantix/OR simultaneously measures the internal diameter of the blood vessel and the velocity profile of the internal blood to calculate volume blood flow.

About Neoprobe

Neoprobe develops and provides innovative surgical and diagnostic products that enhance patient care by meeting the critical decision making needs of healthcare professionals. Neoprobe`s current line of gamma detection systems is widely used for intraoperative lymphatic mapping (ILM), an emerging standard of care technology for breast cancer and melanoma and the detection of radiopharmaceuticals applied throughout the human body`s tissues and organs. Neoprobe also holds significant interests in the development of related biomedical systems and agents. The Company`s strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. With the 2001 acquisition of Cardiosonix Ltd., Neoprobe expanded its product portfolio to include blood flow measurement products. Cardiosonix is engaged in the early stages of commercializing the Quantix(TM) family of flood flow measurement products. Cardiosonix` products are designed to be used by neurosurgeons, cardiovascular surgeons and critical care physicians.

Statements in this news release which relate to other than strictly historical facts are forward-looking statements, and as such are subject to risks and uncertainties, including those detailed in the Company`s most recent Annual Report on Form 10-KSB and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

SOURCE: Neoprobe Corporation

Neoprobe Corporation
Brent L. Larson, 614-793-7500
or
The Trout Group
Jonathan Fassberg, 212-437-9007

http://www.businesswire.com

Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.


Copyright (C) 2003 Business Wire. All rights reserved.


Gruß
DmComeBack
Das ding ist nicht schlecht, aber heute schon zu teuer mit diesem anstieg.

Sop bei 0,15 halte ich es für nen guten kauf.


ist + - o momentan ,steigert sich aber regelmäßig dasist gut
Da hängen 1.500 Stück zu 0,18 im Bid (in Berlin).

Ist das einer von Euch?
;)
Ich bins nicht aber ich würde gerne zu 0,15 welche kaufen, also wer mir 5000 stück zu 0,15-0,16 in berlin gibt, der soll mir kurtz ne email schreiben.

dann muß ich die nicht in amiland kaufen,

also meldet euch
NEOP NEOPROBE CORP | NEOP
Portfolio Tracking Ticker


Sep. 11, 2003 10:07 ET Market Open
Common Stock Market: OTCBB

Last Sale $ 0.24
Change Net / % 0.035 17.07% :lick: :lick:
Best Bid / Ask $ 0.24 $ 0.27 :lick: :lick:
Today`s High / Low $ 0.25 $ 0.20
Share Volume 137,400
Previous Close $ 0.205
52 Wk High / Low $ 0.31 $ 0.05

0,24 als Schlußstand wäre mir schon Recht. Hauptsache es geht langsam hoch. Mal sehen was kommt.
Übrigens der Umsatz am 8.9.03 war der 2.Höchste überhaupt .

Höchster US war am 27.4.98, danach kommt schon der vom Montag.

Chart liegt bis 1992 vor.

Wenn jemand mitzocken will, sollte er wirklich in den USA kaufen.

Gruß
Sep. 11, 2003 11:06 ET Market Open
Common Stock Market: OTCBB

Last Sale $ 0.27
Change Net / % 0.065 31.71%
Best Bid / Ask $ 0.26 $ 0.28 :lick: :laugh:
Today`s High / Low $ 0.29 $ 0.20 :lick: :laugh:
Share Volume 539,400 :lick: :laugh:
Previous Close $ 0.205
52 Wk High / Low $ 0.31 $ 0.05



Von mir aus können die jetzt den Handel für heute einstellen.
Sep. 11, 2003 11:19 ET Market Open
Common Stock Market: OTCBB

Last Sale $ 0.37
Change Net / % 0.165 80.49% :lick: :lick: :laugh:
Best Bid / Ask $ 0.365 $ 0.39
Today`s High / Low $ 0.38 $ 0.20
Share Volume 832,100 :lick: :lick: :laugh:
Previous Close $ 0.205
52 Wk High / Low $ 0.31 $ 0.05


Da werden jetzt bestimmt einige Shortis gegrillt.


WKN: 885701 NEOP

Bitte in den USA ordern. Deutschland ist keine Umsatz.

Gruß
Die 100 % sind voll!

Sep. 11, 2003 15:41 ET Market Open
Common Stock Market: OTCBB

Last Sale $ 0.41 :lick: :laugh:
Change Net / % 0.205 100%
Best Bid / Ask $ 0.38 $ 0.41 :lick: :laugh:
Today`s High / Low $ 0.41 $ 0.20
Share Volume 1,367,000 :lick: :laugh:
Previous Close $ 0.205
52 Wk High / Low $ 0.31 $ 0.05


So jetzt gibts einen guten Wein. :lick: :lick:

Gruß
Heute schon wieder 17%.


NEOP NEOPROBE CORP | NEOP
Portfolio Tracking Ticker


Sep. 12, 2003 10:21 ET Market Open
Common Stock Market: OTCBB

Last Sale $ 0.47
Change Net / % 0.07 17.5%
Best Bid / Ask $ 0.46 $ 0.48
Today`s High / Low $ 0.49 $ 0.42
Share Volume 817,600
Previous Close $ 0.40
52 Wk High / Low $ 0.41 $ 0.05


:lick: :lick:
09/12/2003 (09:56 ET) VOLUME(+): NEOP Volume 59% > 20-adsv, Stock +12.50% - Knobias
09/12/2003 (09:46 ET) 52W HIGH: New 52-Wk High for NEOP @ $0.460 up15.00% - Knobias
09/12/2003 (08:30 ET) News from Neoprobe Corporation: Quantix/ND Neurosurgery Clinical Results Published and Presented; New Technology Permits Bedside Assessment of Blood Flow - Business Wire
09/08/2003 (14:37 ET) BTC: Biotechs Keep Momentum in Late-day Trading - Knobias
09/08/2003 (09:12 ET) Neoprobe Receives Marketing Clearance for Quantix/OR in United States; Quantix/OR To Be Delivered to Clinical Sites - Business Wire


JS200
Bin gestern mit der Hälfte zu 0,47 ausgestiegen.

Der Rest kann jetzt machen was er will. :lick: :laugh:

Schönes Wochenende
DmComeBack


Beitrag zu dieser Diskussion schreiben


Es handelt sich hier um einen ältere Diskussionen, daher ist das Schreiben in dieser Diskussion nicht mehr möglich. Bitte eröffnen Sie hier ein neue Diskussion.